Intervention

Dulaglutide Injection

ClinicalTrials.gov intervention label

Clinical trials4

Recruiting0

Common conditions4

Lead sponsors shown4

Clinical trials

4 shown

A Phase 3 Study of HS-20094 in Patients With T2DMNCT07156539 · 2025-09-30

NOT_YET_RECRUITING

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes MellitusNCT05516966 · 2022-10-12

Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic NephropathyNCT06182891 · 2021-10-30

Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery PatientsNCT03743025 · 2019-03-08

Common conditions

Diabetes Mellitus, Type 21 Stress Hyperglycemia1 Type 2 Diabetes1 Type 2 Diabetic Nephropathy1

Leading sponsors

Emory University1 Fujian Shengdi Pharmaceutical Co., Ltd.1 Jiangsu Hansoh Pharmaceutical Co., Ltd.1 The Affiliated Hospital of Xuzhou Medical University1

Trial status mix

COMPLETED2

NOT_YET_RECRUITING1

TERMINATED1

Phase mix

NA1

PHASE11

PHASE31

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.